WHAT IS CLAIMED IS:

1. A method of stimulating hematopoiesis in a patient in need of treatment, said method comprising administration to said patient of a pharmacologically effective amount of a composition comprising one or more compounds described by formula 1:

$$H_3C(CH_2)_nOH \quad (1)$$

wherein n = 7-11.

2. The method of claim 1, wherein said composition comprises at least decanol.

3. The method of claim 1, wherein said composition comprises at least dodecanol.

4. The method of claim 1, wherein at least one compound of said composition is administered at a concentration greater than 1 μM in blood.

5. The method of claim 1, wherein stimulating hematopoiesis treats myelosuppression arising from chemotherapy in said patient.

6. The method of claim 1, wherein stimulating hematopoiesis treats myelosuppression arising from radiotherapy in said patient.

7. The method of claim 1, wherein stimulating hematopoiesis treats neutropenia arising from chemotherapy in said patient.

8. The method of claim 1, wherein stimulating hematopoiesis treats neutropenia arising from radiotherapy in said patient.

9. The method of claim 1, wherein stimulating hematopoiesis treats anemia arising from chemotherapy in said patient.

10. The method of claim 1, wherein stimulating hematopoiesis treats anemia arising from radiotherapy in said patient.

~~11. The method of claim 1, wherein stimulating hematopoiesis treats neutropenia~~ arising from a hematologic disease, or infection, or a nutritional deficiency, or drug-induced neutropenia in said patient.

12. The method of claim 1, wherein stimulating hematopoiesis treats anemia arising from chronic renal failure, or end-stage renal disease, or arising from a medical or surgical procedure, or drug-induced anemia in said patient.

13. The method of claim 1 further comprising simultaneous administration of a pharmacologically effective amount of a human colony stimulating factor, wherein the pharmacologically effective amount of colony stimulating factor is reduced in the presence of said one or more compounds.

14. The method of claim 1 further comprising separate administration of a pharmacologically effective amount of a human colony stimulating factor, before and/or after administration of one or more compounds, but not simultaneous administration.

15. The method of claim 1 further comprising simultaneous administration of a pharmacologically effective amount of a human erythropoietin, wherein the pharmacologically effective amount of erythropoietin is reduced in the presence of said one or more compounds.

16. The method of claim 1 further comprising separate administration of a pharmacologically effective amount of a human erythropoietin before and/or after administration of one or more compounds, but not simultaneous administration.

17. Use of one or more compounds for the manufacture of a medicament for stimulating hematopoiesis in a patient in need of treatment, said one or more compounds being selected from the group consisting of compounds described by ~~formula 1:~~

$H_3C(CH_2)_nOH$ (1)

wherein n = 7-11.

18. A composition for stimulating hematopoiesis in a patient in need of treatment, said composition comprising a pharmacologically effective amount of a composition comprising one or more compounds described by formula 1:

$H_3C(CH_2)_nOH$ (1)

wherein n = 7-11.

19. The composition of claim 18, wherein said composition comprises at least decanol.

20. The composition of claim 18, wherein said composition comprises at least dodecanol.

CLAIMS:

1. Use of a composition comprising one or more compounds described by formula 1:

$$H_3C(CH_2)_nOH \qquad (1)$$

wherein n = 7-11, for the manufacture of a medicament for stimulating hematopoiesis in a patient in need of treatment.

2. The use of claim 1, wherein said composition comprises at least decanol.

3. The use of claim 1, wherein said composition comprises at least dodecanol.

4. The use of any one of claims 1-3, wherein at least one compound of said composition is administered to achieve a concentration greater than 1 μM in blood.

5. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with myelosuppression arising from chemotherapy.

6. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with myelosuppression arising from radiotherapy.

7. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with neutropenia arising from chemotherapy.

8. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with neutropenia arising from radiotherapy.

9. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with anemia arising from chemotherapy.

10. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with anemia arising from radiotherapy.

11. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with neutropenia arising from a hematologic disease, or infection, or a nutritional deficiency, or drug-induced neutropenia.

12. The use of any one of claims 1-4, wherein said composition stimulates hematopoiesis in patients with anemia arising from chronic renal failure, or end-stage renal disease, or arising from a medical or surgical procedure, or drug-induced anemia.

13. The use of any one of claims 1-12, wherein said composition is administered simultaneously with a pharmacologically effective amount of a human colony stimulating factor, and wherein the pharmacologically effective amount of colony stimulating factor is reduced in the presence of said composition.

14. The use of any one of claims 1-12, wherein said composition is administered separately from a pharmacologically effective amount of a human colony stimulating factor, and wherein administration may be before and/or after administration of said composition but not simultaneously administration.

15. The use of any one of claims 1-12, wherein said composition is administered simultaneously with a pharmacologically effective amount of a erythropoietin, wherein the pharmacologically effective amount of erythropoietin is reduced in the presence of said composition.

16. The use of any one of claims 1-12, wherein said composition is administered separately from a pharmacologically effective amount of a human erythropoietin, wherein administration may be before and/or after administration of said composition but not simultaneously administration.

17. A composition comprising a pharmacologically effective amount of one or more compounds described by formula 1:

$$H_3C(CH_2)_nOH \qquad (1)$$

wherein n = 7-11 for use in stimulating hematopoiesis in a patient in need of treatment.

18. The composition of claim 17, wherein said composition comprises at least decanol.

19. The composition of claim 17, wherein said composition comprises at least dodecanol.

20. The composition of any one of claims 17-19, wherein said composition further comprises a pharmacologically effective amount of a human colony stimulating factor.

21. The composition of any one of claims 17-19, wherein said composition further comprises a pharmacologically effective amount of a human erythropoietin.

22. One or more compounds selected from the group consisting of compounds described by formula 1 :

$$H_3C(CH_2)_nOH \qquad (1)$$

wherein n = 7-11, for use in increasing the number of red and/or white blood cells in a patient in need of treatment.

23. The use of claim 22, wherein the compound consists of decanol.